HUBER NEEDLE -ONCO GRIP

Informazioni principali

  • Nome commerciale:
  • HUBER NEEDLE -ONCO GRIP
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Dispositivo medico

Documenti

  • per il pubblico:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per il pubblico.

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • HUBER NEEDLE -ONCO GRIP
    Italia
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • AGHI E KIT PER SISTEMI IMPIANTABILI

Altre informazioni

Status

  • Fonte:
  • Ministero della Salute - Italia
  • Stato dell'autorizzazione:
  • S
  • Data dell'autorizzazione:
  • 17-03-2010
  • Ultimo aggiornamento:
  • 09-08-2016
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.

    Richiedi il foglio illustrativo per il pubblico.

6-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA’s new effort for developing and class labeling of in vitro companion diagnostics for classes of oncology therapeutic products

Statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA’s new effort for developing and class labeling of in vitro companion diagnostics for classes of oncology therapeutic products

Statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA’s new effort for developing and class labeling of vitro companion diagnostics for classes of oncology therapeutic products

FDA - U.S. Food and Drug Administration

26-11-2018

FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

The FDA granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).

FDA - U.S. Food and Drug Administration

5-11-2018

STIHL Limited recalls STIHL MSA 161 T Battery Operated Arborist Chain Saw

STIHL Limited recalls STIHL MSA 161 T Battery Operated Arborist Chain Saw

The side inter-lock button may stick when gripping the machine, which could cause the throttle trigger to remain depressed and the chain to continue to run even after releasing the throttle trigger. This can pose a risk of laceration to the user or bystander.

Health Canada

17-10-2018

Applicability of in silico tools for the prediction of dermal absorption for pesticides

Applicability of in silico tools for the prediction of dermal absorption for pesticides

Published on: Tue, 16 Oct 2018 00:00:00 +0200 Based on the “Human in vitro dermal absorption datasets” published as supporting information to the revised EFSA Guidance on Dermal Absorption, in silico models for prediction of absorption across the skin have been evaluated. For this evaluation, a systematic literature search and review was performed, identifying 288 publications describing mathematical models for prediction of dermal absorption. Eleven models potentially relevant to the regulatory assessm...

Europe - EFSA - European Food Safety Authority Publications

13-9-2018

October 10, 2018: Meeting of the Oncologic Drugs Advisory Committee

October 10, 2018: Meeting of the Oncologic Drugs Advisory Committee

October 10, 2018: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement

FDA - U.S. Food and Drug Administration

26-7-2018

Opinion/decision on a Paediatric investigation plan (PIP):    Ninlaro, Ixazomib, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): Ninlaro, Ixazomib, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

25-7-2018

Opinion/decision on a Paediatric investigation plan (PIP):    -, Enfortumab vedotin, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): -, Enfortumab vedotin, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

18-7-2018

FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency

FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency

FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency

FDA - U.S. Food and Drug Administration

12-7-2018

Oncologic Drugs Advisory Committee Roster

Oncologic Drugs Advisory Committee Roster

This page contains the ODAC roster, which lists the current members and the current number of vacancies for the committee.

FDA - U.S. Food and Drug Administration

19-6-2018

Opinion/decision on a Paediatric investigation plan (PIP):    -, Pevonedistat, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): -, Pevonedistat, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

19-6-2018

Opinion/decision on a Paediatric investigation plan (PIP):    -, Niraparib, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): -, Niraparib, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

19-6-2018

Opinion/decision on a Paediatric investigation plan (PIP):    -, Durvalumab, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): -, Durvalumab, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

19-6-2018

Opinion/decision on a Paediatric investigation plan (PIP):    -, Tremelimumab, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): -, Tremelimumab, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

19-6-2018

Opinion/decision on a Paediatric investigation plan (PIP):    -, Veliparib, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): -, Veliparib, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

6-6-2018

Opinion/decision on a Paediatric investigation plan (PIP):    -, Quizartinib, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): -, Quizartinib, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

6-6-2018

Opinion/decision on a Paediatric investigation plan (PIP):    -, Binimetinib, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): -, Binimetinib, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

6-6-2018

Opinion/decision on a Paediatric investigation plan (PIP):    -, Encorafenib, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): -, Encorafenib, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

6-6-2018

Opinion/decision on a Paediatric investigation plan (PIP):    Rydapt, Midostaurin, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): Rydapt, Midostaurin, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

6-6-2018

Opinion/decision on a Paediatric investigation plan (PIP):    -, Selumetinib, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): -, Selumetinib, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

22-5-2018

May 21, 2018: Oncologist and Office Manager Sentenced in Connection with Administering Unapproved, Foreign Drugs

May 21, 2018: Oncologist and Office Manager Sentenced in Connection with Administering Unapproved, Foreign Drugs

May 21, 2018: Oncologist and Office Manager Sentenced in Connection with Administering Unapproved, Foreign Drugs

FDA - U.S. Food and Drug Administration

16-4-2018

Acupuncture needles with false CE marking

Acupuncture needles with false CE marking

Sterile acupuncture needles with false CE marking are sold online. We ask you to pay attention to these products because there is no documentation to support the product's sterility or the materials used to fabricate the device.

Danish Medicines Agency

14-12-2018

#ICYMI: @SGottliebFDA issued a statement on the #FDA’s new effort for  developing and class labeling of in vitro companion diagnostics for classes of oncology therapeutic products. Read the statement here:  https://go.usa.gov/xE3kk  #MedicalDevice

#ICYMI: @SGottliebFDA issued a statement on the #FDA’s new effort for developing and class labeling of in vitro companion diagnostics for classes of oncology therapeutic products. Read the statement here: https://go.usa.gov/xE3kk  #MedicalDevice

#ICYMI: @SGottliebFDA issued a statement on the #FDA’s new effort for developing and class labeling of in vitro companion diagnostics for classes of oncology therapeutic products. Read the statement here: https://go.usa.gov/xE3kk  #MedicalDevice

FDA - U.S. Food and Drug Administration

11-12-2018

Rubraca (Clovis Oncology Ireland Limited)

Rubraca (Clovis Oncology Ireland Limited)

Rubraca (Active substance: rucaparib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8686 of Tue, 11 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4272/T/5

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2071 (Loxo Oncology Limited)

EU/3/18/2071 (Loxo Oncology Limited)

EU/3/18/2071 (Active substance: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile) - Orphan designation - Commission Decision (2018)7272 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/125/18

Europe -DG Health and Food Safety

25-10-2018

Canigen L4 (Intervet International B.V.)

Canigen L4 (Intervet International B.V.)

Canigen L4 (Active substance: Leptospira interrogans serogroup Canicola serovar Portland-vere/Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni/Leptospira interrogans serogroup Australis serovar Bratislava/Leptospira kirschneri serogroup Grippotyphosa serovar Dadas) - Centralised - Yearly update - Commission Decision (2018)7138 of Thu, 25 Oct 2018

Europe -DG Health and Food Safety

27-9-2018

We want to help patients/caregivers know how to use pen needles correctly. FDA received reports of patients using standard pen needles to inject insulin w/o removing the inner needle cover. The cover stopped patients from getting the right amnt of insulin

We want to help patients/caregivers know how to use pen needles correctly. FDA received reports of patients using standard pen needles to inject insulin w/o removing the inner needle cover. The cover stopped patients from getting the right amnt of insulin

We want to help patients/caregivers know how to use pen needles correctly. FDA received reports of patients using standard pen needles to inject insulin w/o removing the inner needle cover. The cover stopped patients from getting the right amnt of insulin https://go.usa.gov/xPWZq  pic.twitter.com/LT9SptJge1

FDA - U.S. Food and Drug Administration

22-8-2018

Gripovac 3 (Merial)

Gripovac 3 (Merial)

Gripovac 3 (Active substance: Not available) - Centralised - Withdrawal - Commission Decision (2018)5633 of Wed, 22 Aug 2018

Europe -DG Health and Food Safety

11-7-2018

Concorsi AIFA 2018 - Diario delle prove scritte

Concorsi AIFA 2018 - Diario delle prove scritte

L'Agenzia Italiana del Farmaco comunica il diario delle prove scritte relative ai Concorsi AIFA 2018.

Italia - AIFA - Agenzia Italiana del Farmaco

29-5-2018

Rubraca (Clovis Oncology UK Limited)

Rubraca (Clovis Oncology UK Limited)

Rubraca (Active substance: rucaparib) - Centralised - Authorisation - Commission Decision (2018)3344 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4272

Europe -DG Health and Food Safety

15-5-2018

Pemetrexed Fresenius Kabi (Fresenius Kabi Oncology Plc.)

Pemetrexed Fresenius Kabi (Fresenius Kabi Oncology Plc.)

Pemetrexed Fresenius Kabi (Active substance: pemetrexed) - Centralised - Yearly update - Commission Decision (2018)3060 of Tue, 15 May 2018

Europe -DG Health and Food Safety

23-3-2018

EU/3/18/1995 (Loxo Oncology Limited)

EU/3/18/1995 (Loxo Oncology Limited)

EU/3/18/1995 (Active substance: Larotrectinib) - Orphan designation - Commission Decision (2018)1884 of Fri, 23 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/213/17

Europe -DG Health and Food Safety

21-3-2018

Accesso alle terapie con farmaci biologici: i fenomeni di sottotrattamento e le opportunità offerte dai biosimilari

Accesso alle terapie con farmaci biologici: i fenomeni di sottotrattamento e le opportunità offerte dai biosimilari

I farmaci biologici costituiscono un’arma importante per superare il problema del sottotrattamento e rendere disponibili terapie a un numero sempre maggiore di pazienti, in particolare nelle aree dell’oncologia, reumatologia, gastroenterologia e dermatologia.

Italia - AIFA - Agenzia Italiana del Farmaco